Your browser doesn't support javascript.
loading
Non-invasive heart failure monitoring: leveraging smart scales and digital biomarkers to improve heart failure outcomes.
Wattanachayakul, Phuuwadith; Kittipibul, Veraprapas; Salah, Husam M; Yaku, Hidenori; Nuñez, Julio; De la Espriella, Rafael; Biering-Sørensen, Tor; Fudim, Marat.
Affiliation
  • Wattanachayakul P; Department of Medicine, Jefferson Einstein Hospital, Philadelphia, PA, USA.
  • Kittipibul V; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
  • Salah HM; Division of Cardiology, Department of Internal Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Yaku H; Duke Clinical Research Institute, 300 W. Morgan Street, Durham, NC, 27701, USA.
  • Nuñez J; Division of Cardiology, Department of Internal Medicine, Duke University School of Medicine, Durham, NC, USA.
  • De la Espriella R; Division of Cardiology, Department of Medicine, and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Biering-Sørensen T; Department of Medicine, Universitat de València, Valencia, Spain.
  • Fudim M; Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.
Heart Fail Rev ; 29(5): 1145-1156, 2024 Sep.
Article de En | MEDLINE | ID: mdl-39039364
ABSTRACT
Heart failure (HF) is a significant global concern, impacting patient morbidity, mortality, and healthcare costs. Guideline-directed medical therapy and various preventive measures have proven effective in improving clinical outcomes and reducing HF hospitalizations. Recent data indicates that remote HF monitoring facilitates early detection of HF decompensation by observing upstream events and parameters before clinical signs and symptoms manifest. Moreover, these innovative devices have been shown to decrease unnecessary HF hospitalizations and, in some cases, provide predictive insights before an actual HF incident. In this review, we aim to explore the data regarding smart scales and digital biomarkers and summarize both FDA-approved devices and emerging technologies by assessing their clinical utility, mechanism of HF decompensation detection, and ongoing trials. Furthermore, we also discuss the future trend of integrating these devices into routine clinical practice to improve patient clinical outcomes.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Marqueurs biologiques / Défaillance cardiaque Limites: Humans Langue: En Journal: Heart Fail Rev Sujet du journal: CARDIOLOGIA Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Marqueurs biologiques / Défaillance cardiaque Limites: Humans Langue: En Journal: Heart Fail Rev Sujet du journal: CARDIOLOGIA Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique